Fecal calprotectin concentrations in cancer patients with Clostridium difficile infection
- PMID: 30242543
- PMCID: PMC6230305
- DOI: 10.1007/s10096-018-3381-9
Fecal calprotectin concentrations in cancer patients with Clostridium difficile infection
Abstract
Fecal calprotectin (fCPT) has been used as a surrogate marker for assessment of intestinal inflammation. We explore the utility of fCPT values as a diagnostic aid in cancer patients with suspected Clostridium difficile infection (CDI). A total of 232 stool specimens submitted for GeneXpert C. difficile PCR testing were included in the study. All specimens were tested for fCPT and toxin/GDH antigens. Clinical severity of CDI cases was determined by the IDSA/SHEA criteria. Significant differences of median fCPT values between CDI (n = 117, Median 183.6 μg/g) and non-CDI (n = 115, 145.6 μg/g, p = 0.006) patients were seen. In CDI patents, significantly lower fCPT values were found in patients with mild to moderate (n = 95, 182.1 μg/g) than those with severe and severe to complicated (n = 22, 218.5 μg/g, p = 0.014) scores, and among those that were toxin positive (n = 24, 200.2 μg/g) vs. toxin negative (n = 86, 182.8 μg/g, p = 0.044). Despite this overall trend, wide variations in fCPT values were found in all categories examined. A logistic regression analysis revealed that the fCPT values correlated independently with the severity of clinical manifestations (OR = 2.021, 95%CI = 1.132-3.608); however, it did not correlate with other clinical outcomes. Our study findings show that high fecal calprotectin levels correlate with toxin-positive and clinically severe CDI; however, wide variations in individual measurements preclude establishment of reliable cut-offs for routine diagnostic use in cancer patients.
Keywords: Clostridium difficile infection; Colonization; Fecal calprotectin; PCR.
Conflict of interest statement
Conflict of Interest: The Phical Test was provided free of charge. No other reported conflicts.
Similar articles
-
Ribotype 027 Clostridium difficile infections with measurable stool toxin have increased lactoferrin and are associated with a higher mortality.Eur J Clin Microbiol Infect Dis. 2014 Jun;33(6):1045-51. doi: 10.1007/s10096-013-2043-1. Epub 2014 Jan 22. Eur J Clin Microbiol Infect Dis. 2014. PMID: 24449345 Free PMC article.
-
Correlation between fecal calprotectin levels, disease severity and the hypervirulent ribotype 027 strain in patients with Clostridium difficile infection.BMC Infect Dis. 2016 Jun 22;16:309. doi: 10.1186/s12879-016-1618-8. BMC Infect Dis. 2016. PMID: 27334992 Free PMC article.
-
Elevated fecal calprotectin associates with adverse outcomes from Clostridium difficile infection in older adults.Infect Dis (Lond). 2016 Sep;48(9):663-9. doi: 10.1080/23744235.2016.1186832. Epub 2016 May 20. Infect Dis (Lond). 2016. PMID: 27206404 Free PMC article.
-
The prognostic value of toxin B and binary toxin in Clostridioides difficile infection.Gut Microbes. 2021 Jan-Dec;13(1):1884516. doi: 10.1080/19490976.2021.1884516. Epub 2021 Mar 4. Gut Microbes. 2021. PMID: 33660568 Free PMC article. Review.
-
C. difficile biomarkers, pathogenicity and detection.Clin Chim Acta. 2024 May 15;558:119674. doi: 10.1016/j.cca.2024.119674. Epub 2024 Apr 14. Clin Chim Acta. 2024. PMID: 38621586 Review.
Cited by
-
The value of fecal calprotectin in Clostridioides difficile infection: A systematic review.Front Physiol. 2022 Aug 3;13:881816. doi: 10.3389/fphys.2022.881816. eCollection 2022. Front Physiol. 2022. PMID: 35991191 Free PMC article.
-
Diagnostic Guidance for C. difficile Infections.Adv Exp Med Biol. 2024;1435:33-56. doi: 10.1007/978-3-031-42108-2_3. Adv Exp Med Biol. 2024. PMID: 38175470
-
Preservation of the Innate Immune Response to Clostridioides difficile Infection in Hospitalized Immunocompromised Patients.Open Forum Infect Dis. 2023 Feb 18;10(3):ofad090. doi: 10.1093/ofid/ofad090. eCollection 2023 Mar. Open Forum Infect Dis. 2023. PMID: 36949876 Free PMC article.
-
Microbiome profile and calprotectin levels as markers of risk of recurrent Clostridioides difficile infection.Front Cell Infect Microbiol. 2023 Sep 13;13:1237500. doi: 10.3389/fcimb.2023.1237500. eCollection 2023. Front Cell Infect Microbiol. 2023. PMID: 37780848 Free PMC article.
-
The Immune Protein Calprotectin Impacts Clostridioides difficile Metabolism through Zinc Limitation.mBio. 2019 Nov 19;10(6):e02289-19. doi: 10.1128/mBio.02289-19. mBio. 2019. PMID: 31744916 Free PMC article.
References
-
- Lessa FC, Mu Y, Bamberg WM, Beldavs ZG, Dumyati GK, Dunn JR, Farley MM, Holzbauer SM, Meek JI, Phipps EC, Wilson LE, Winston LG, Cohen JA, Limbago BM, Fridkin SK, Gerding DN, McDonald LC (2015) Burden of Clostridium difficile infection in the United States. The New England journal of medicine 372 (9):825–834 - PMC - PubMed
-
- Dominguez SR, Dolan SA, West K, Dantes RB, Epson E, Friedman D, Littlehorn CA, Arms LE, Walton K, Servetar E, Frank DN, Kotter CV, Dowell E, Gould CV, Hilden JM, Todd JK (2014) High colonization rate and prolonged shedding of Clostridium difficile in pediatric oncology patients. Clinical infectious diseases : an official publication of the Infectious Diseases Society of America 59 (3):401–403 - PMC - PubMed
-
- Loo VG, Bourgault AM, Poirier L, Lamothe F, Michaud S, Turgeon N, Toye B, Beaudoin A, Frost EH, Gilca R, Brassard P, Dendukuri N, Beliveau C, Oughton M, Brukner I, Dascal A (2011) Host and pathogen factors for Clostridium difficile infection and colonization. The New England journal of medicine 365 (18):1693–1703 - PubMed
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical